The primary objective of the phase 3b SOUL trial was to evaluate the effects of oral semaglutide 14 mg, in addition to standard of care, on reducing the risk of MACE in adults with type 2 diabetes at high risk for major cardiovascular events
Liraglutide, marketed under names like Victoza and Saxenda, typically requires daily injections and is approved at different dosages for diabetes and weight management
nasal language, references to tanning strengths)
Combining semaglutide with counseling or appropriate psychiatric care ensures holistic wellness during weight loss treatment
For moderate weight loss, metabolic tuning, inflammation, and even heart-protective benefits, lower doses may be enough for some people
They must either have: BMI of at least 35BMI of at least 30 plus a history of heart failure, uncontrolled hypertension or chronic kidney diseaseBMI of at least 27 plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease